Clinical trial · Interventional
Intraoperative Radiotherapy for Early Stage Breast Cancer
Intraoperative Radiotherapy (IORT) for the Management of Carcinoma of the Breast: Use of Mammography, Ultrasonography,and Contrast-Enhanced Magnetic Resonance Imaging (CE-MRI) to Identify Candidates for IORT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Up to 200 patients with biopsy proven early stage breast cancer selecting Wide Local Excision (WLE) will undergo mammography, ultrasound (of affected breast and ipsilateral axilla) and contrast enhanced-magnetic resonance imaging (CE-MRI) of the affected breast to evaluate the extent of disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intraoperative Radiotherapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- IORT
- description
- Treated with Intraoperative Radiation Therapy
- interventionNames
- Device: Intraoperative Radiotherapy
Primary outcomes (1)
- measure
- Proportion of Participants Receiving Additional Surgery Because of Positive or Close Margins as a Measure of the Accuracy of Pre-Operative Assessment
- timeFrame
- 10 years
- description
- Invasive cancer margins \<1 mm and/or non-invasive cancer margins \< 2 mm are considered close or positive. Approximately 15% of patients treated with IORT have close or positive margins on pathologic assessment following IORT therapy and are recommended for additional therapy including re-excision, whole breast radiation or both.
Secondary outcomes (5)
- measure
- Proportion of Participants Recommended to Have Additional Whole Breast Radiation Therapy (WBRT) Because of High Risk Features Found on Final Pathology as a Measure of the Accuracy of Pre-Operative Assessment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 48 Years
Show eligibility criteria text
Inclusion Criteria: 1. Informed Consent. Each eligible patient must willingly give written consent after being informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts. 2. Histology. Patients must have biopsy-proven invasive ductal or lobular carcinoma of the breast. 3. Female, age ≥ 48 years. 4. Clinically and/or histologically negative axillary lymph nodes. 5. No imaging or clinical findings that indicate metastatic disease. 6. Procedure deemed appropriate based upon factors such as breast size by the treating surgeon and radiation oncologist. Exclusion Criteria: 1. Male sex 2. Age \< 48 3. Non-epithelial breast malignancies such as sarcoma, lymphoma, or metastatic breast cancer 4. Pregnancy or lactation 5. Serious psychiatric or addictive disorders 6. More than one obvious cancer in the same breast as diagnosed by clinical examination, mammography, ultrasonography, and/or CE-MRI. 7. Bilateral breast cancer at the time of diagnosis, unless agreed upon by the surgeon and radiation oncologist. 8. Ipsilateral breast with a previous cancer and/or irradiation. 9. Extensive Intraductal Component (DCIS ≥ 25% of the tumor). 10. Patients presenting with gross nodal disease considered to be clinically malignant by scanning or proven cytologically or by sentinel node biopsy will be cancelled. 11. Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater. 12. Lymphovascular invasion on needle biopsy. 13. Patients undergoing primary medical treatment (hormones or chemotherapy) as initial treatment with intent to reduce tumor size.
References
Publications (0)
Data not yet available